Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Genostics Invests $13.5 Million in UK's Oncimmune for China Rights to Lung Cancer Test

publication date: Jan 4, 2018

Genostics, a Hong Kong diagnostics company, will acquire China rights to Oncimmune’s blood-based cancer testing platform in return for a $13.5 million investment into the UK-based company's shares. Initially, Genostics will bring Oncimmune's EarlyCDT®-Lung to China. The product is an early, blood-based lung cancer screening test for use in smokers who have not shown symptoms of the disease. Oncimmune will receive a royalty of 8% on the gross revenue, with minimum royalty payments of $21 million over the first six years and $7 million per year thereafter. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital